Literature DB >> 15061660

The fluoroquinolones: how long will their utility last?

Johan S Bakken1.   

Abstract

Injudicious use of the fluoroquinolones may result in treatment failure, increased patient morbidity, increased health care cost, and possible patient fatality. Fluoroquinolone-resistant bacteria may also adversely impact the microbiological environment in the hospital, the local community and eventually large geographical regions. Fluoroquinolone resistance develops in a stepwise fashion, and current susceptibility testing methods and recommended MIC susceptible breakpoint values for the United States may fail to identify some bacteria that are resistant due to first step mutations at the fluoroquinolone target site gene sequences. C-8 methoxy- fluoroquinolone compounds are more active against resistant bacteria than the older compounds. Fluoroquinolone resistance relates directly to human and veterinary usage and emerging bacterial resistance poses the single greatest threat to the future survival of the fluoroquinolone drugs as an antibiotic class.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15061660     DOI: 10.1080/00365540410019039

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  9 in total

Review 1.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Community-acquired antibiotic resistance in urinary isolates from adult women in Canada.

Authors:  Warren J McIsaac; Tony Mazzulli; Joanne Permaul; Rahim Moineddin; Donald E Low
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-11       Impact factor: 2.471

3.  The management of acute uncomplicated cystitis in adult women by family physicians in Canada.

Authors:  Warren J McIsaac; Preeti Prakash; Susan Ross
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

4.  Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves.

Authors:  M Raipuria; V K Dumka; H S Sandhu
Journal:  Vet Res Commun       Date:  2007-02-01       Impact factor: 2.816

5.  Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves.

Authors:  Vinod K Dumka; Anil K Srivastava
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

6.  Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy.

Authors:  Shuxiong Zeng; Zhensheng Zhang; Yu Bai; Yinghao Sun; Chuanliang Xu
Journal:  Cochrane Database Syst Rev       Date:  2019-02-21

7.  Disposition kinetics and dosage regimen of levofloxacin on concomitant administration with paracetamol in crossbred calves.

Authors:  Vinod K Dumka
Journal:  J Vet Sci       Date:  2007-12       Impact factor: 1.672

Review 8.  Antibiotic prophylaxis for urinary tract infections after removal of urinary catheter: meta-analysis.

Authors:  Jonas Marschall; Christopher R Carpenter; Susan Fowler; Barbara W Trautner
Journal:  BMJ       Date:  2013-06-11

9.  Prevalence of coagulase-positive methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in dogs in Bangladesh.

Authors:  Eaftekhar Ahmed Rana; Md Zohorul Islam; Tridip Das; Avijit Dutta; Abdul Ahad; Paritosh Kumar Biswas; Himel Barua
Journal:  Vet Med Sci       Date:  2021-12-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.